

TriCore Reference Laboratories
Non-Hospital Antibigram
Gram Positive Isolates 2010

% Susceptible (A)

ORGANISMS (N)	Ampicillin	Cefazolin	Ceftriaxone	Clindamycin	Erythromycin	Gentamicin	Nitrofurantoin (G)	Minocycline	Moxifloxacin	Oxacillin	Penicillin	Trimeth/Sulfa	Tetracycline	Vancomycin	TRICORE REFERENCE LABORATORIES
<i>Staphylococcus aureus</i> (3922)	(-)	50.2	ISD*	87.8	-	98.9	100	98.7	61.6	50.2	-	98.7	96.5	100	Linezolid = 99.9%S; Daptomycin 100%S; Rifampin 99.7%S
<i>Staphylococcus haemolyticus</i> (46)	-	ND	ND	90.9	-	82.6	100	100	67.4	-	-	ND	84.8	100	
<i>Staphylococcus epidermidis</i> (215)	-	ND	ND	64.1	-	100	96	100	66.8	-	-	ISD*	81.4	99.5	
<i>Staphylococcus lugdunensis</i> (71)	-	ND	ND	97	80	100	ISD*	100	97.2	100	-	ND	94.3	98.6	
<i>Streptococcus agalactiae</i> (Group B) (66)	See Pcn	ND	100	60.8	-	ND	ND	ND	ND	ND	100	ND	-	100	Levofloxacin=98.6%S; Linezolid=100%S; Neither drug is approved for treatment of carriers (e.g. pre-partum females)
<i>Streptococcus pneumoniae</i> (68)	See Pcn	See Pcn	98.5/88.2 (C)	81.5	59.2	ND	ND	ND	97.1	ND	78.8/77.6 (B)	76.5	82.4	100	Levofloxacin=98.2%S; Linezolid=100%S
<i>Speciated alpha-hemolytic Streptococci</i> (52) (D)	See Pcn	See Pcn	93.9	77.3	ND	ND	ND	ND	ND	ND	62.7	ND	ND	100	Levofloxacin=97.6%S; Linezolid=100%S
<i>Enterococcus faecalis</i> (1641)	99.1	-	-	-	-	77.1(F)	99.1	ND	ND	ND	See Amp	ND	ND	99.2	Linezolid=92.7%S Daptomycin=100%S
<i>Enterococcus faecalis</i> (132) (E)	28.5	-	-	ND	-	83.3(F)	ND	ND	ND	ND	See Amp	-	-	60	Linezolid=79.5%S; Daptomycin=83.3%S

(-) Antibiotics in white are not active against, or resistance is $\leq 50\%$; shaded bars $S \geq 50\%$; ND = No data; ISD* = insufficient data.

A. Data evaluated per CLSI (NCCLS) M100-S20 and M39 documents; Data sources are TriCore EpiCenter & Eurofins®

B. *S. pneumoniae penicillin breakpoints*: Meningitis (lower); $S \leq 0.06$, $R \geq 0.12$; Nonmeningitis (upper), $S < 2$, $I = 4.0$, $R \geq 8$ mcg/ml

C. *S. pneumoniae ceftriaxone breakpoints*: Meningitis lower); $S \leq 0.5$, $I = 1.0$, $R \geq 2.0$; Nonmeningitis (upper); $S < 1.0$; $I = 2.0$, $R \geq 4.0$ mcg/ml

D. Viridans Streptococci (n=52); α -streptococci; *S. anginosus*; *S. intermedius*; *S. parasanguinis*; *S. gordonii*; *S. oralis*; *S. mitis* & *mitis* group.

E. Serious enterococcal infections may require the use of an active cell wall antibiotic (e.g. ampicillin or vancomycin) and gentamicin or streptomycin.

F. Gentamicin susceptibility is for synergy only; always must include a cell wall antibiotic; never alone.

G. Nitrofurantoin is approved only for the treatment of UTI.

DRAFT 05/18/11; FINAL